background: The aim of this meta-analysis was to evaluate the association of progesterone elevation (PE) on the day of hCG administration with the probability of pregnancy in fresh, frozen-thawed and donor/recipient IVF cycles.
Introduction
The introduction of ovarian stimulation has been followed by a constant effort to fine-tune the physiology of the stimulated cycle and optimize the probability of pregnancy after IVF. In this respect, the role of progesterone elevation (PE) on the day of hCG administration in GnRH analogue cycles has been under the spotlight for over 20 years (Schoolcraft et al., 1991; Silverberg et al., 1991; Fanchin et al., 1993; Ubaldi et al., 1995; Urman et al., 1999; Bosch et al., 2003 Bosch et al., , 2010 Papanikolaou et al., 2005; Check et al., 2009; Huang et al., 2012a) .
Since the first report by Schoolcraft et al. (1991) , there have been numerous publications, however, with contradictory results. A systematic review of the relevant studies published until 2006, showed a lower, although not significantly so, pregnancy rate in the presence of PE (Venetis et al., 2007) . A subsequent review, focusing on studies evaluating only GnRH-antagonist cycles published until June 2010, suggested that in the presence of PE a significantly lower probability of pregnancy should be expected after IVF .
Obviously, the issue is still far from resolved. Certain clinicians highly doubt the presence of an association between PE and the probability of pregnancy and do not monitor progesterone on the day of hCG, while others have implemented specific strategies in order to avoid or manage PE.
Moreover, several secondary clinical questions remain unanswered. What is the incidence of PE? Is it dependent upon the population examined or the type of gonadotrophins used for ovarian stimulation? If a detrimental effect is indeed present, is it universal across all types of IVF populations (poor, normal or high responders)? Is PE on the day of hCG administration in the fresh cycle associated with a decreased chance of pregnancy in women undergoing frozen -thawed embryo transfer or in those receiving oocytes from donors?
In the last 2 years, a substantial number of additional studies has been published, many of which evaluated the association of PE with the probability of pregnancy in thousands of patients (Bosch et al., 2010; Seow et al., 2010; Yu et al., 2010; Cohen-Bacrie et al., 2012; Gordon et al., 2012; Wu et al., 2012; Xu et al., 2012) .
Considering the marked increase in the published data, a systematic appraisal of the available evidence was considered essential in order to confidently evaluate the association of PE and the probability of pregnancy achievement and provide answers to the aforementioned secondary clinical questions.
Methods
A computerized literature search in MEDLINE, SCOPUS, CENTRAL and Web of Science covering the period until August 2012 was performed independently by two reviewers (C.A.V. and J.K.B.) aiming to identify relevant studies. For this purpose, a search strategy with keywords targeting the term 'PE' combined with the term 'IVF' was constructed. Various synonyms describing each term were entered as free-text terms in the electronic databases in an attempt to maximize the sensitivity of the search strategy (Supplementary data, Table SI ). Additionally, the citation lists of all relevant publications and review articles were hand-searched. Meeting proceedings of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine were also hand-searched for the identification of relevant studies. No language limitations were applied (i.e. studies published in a language other than English were also considered eligible).
The predefined criteria for inclusion of a study in this systematic review were: (a) the study had to evaluate women undergoing fresh or frozenthawed embryo transfer or women undergoing embryo transfer with donated oocytes; (b) the study had to provide extractable data on pregnancy rates among women classified as those with, and those without, PE on the day of hCG administration; and (c) ovarian stimulation should have been performed with the use of gonadotrophins and GnRH analogues. Studies in which ovarian stimulation was performed with the concomitant use of anti-estrogens or without the use of GnRH analogues were not eligible. Moreover, all studies in which (a) it was reported that the level of progesterone on the day of hCG administration affected patient management or (b) the number of embryos transferred was significantly different between those patients with and those without PE, were excluded. Selection of the studies was performed independently by two of the reviewers (C.A.V. and E.M.K.). Any disagreement was resolved by discussion.
Data extraction was performed independently by two of the reviewers (C.A.V. and E.M.K.). The following data were recorded from the eligible studies, where applicable: demographic (citation data, country, study period, type of population, number of cycles and number of patients included); methodological (PE threshold and reason for choosing this threshold, details regarding the assay used to determine progesterone concentration); and procedural (type of gonadotrophin used for ovarian stimulation, type of GnRH analogue and protocol used for LH surge inhibition, day of embryo transfer, type of endometrial preparation in frozenthawed cycles). Any disagreement between the two reviewers responsible for data extraction was resolved by discussion.
The main outcome measure chosen for the current meta-analysis was achievement of pregnancy. To calculate this outcome, data from each study were primarily extracted on ongoing pregnancy (≥12 weeks of gestation)/live birth and if not available, then data on clinical pregnancy (up to 6 -8 weeks of gestation) were used. This was performed in order to increase the statistical power of this meta-analysis by analysing all eligible studies offering data on the association of PE with the probability of pregnancy achievement. The use of achievement of pregnancy as a primary outcome of this meta-analysis was based on the assumption that the effect sizes of PE for ongoing pregnancy/live birth and clinical pregnancy are comparable, i.e. the evolution of pregnancy from clinical to ongoing pregnancy/live birth is not affected by the presence of PE on the day of hCG administration. To test for this hypothesis, the correlation and the concordance between the odds ratios (ORs) of clinical pregnancy and the ORs of ongoing pregnancy/live birth were calculated by using data from studies that reported both outcome measures (n ¼ 23). Both the Spearman's rho coefficient (r ¼ 0.94; P , 0.001) and the Lin's concordance correlation coefficient [r c ¼ 0.92, 95% confidence interval (CI): 0.81 -0.96] (Lin, 1989) indicated good correlation and reproducibility. However, for reasons of completeness, the pooled ORs regarding clinical pregnancy and ongoing pregnancy/live birth are also reported separately.
Secondary outcome measures in the fresh IVF cycles included duration of gonadotrophin stimulation, total dose of follicle-stimulating hormone (FSH) required for ovarian stimulation, number of cumulus -oocyte complexes (COCs) retrieved and estradiol levels (E 2 ) on the day of hCG.
The dichotomous data for each of the eligible studies were extracted in a 2 × 2 table and expressed as the OR with 95% CI. When crosstabulation of data was not feasible, ORs with 95% CIs were extracted where available. These data were extracted on the PE threshold values provided by each study or dataset. When a study provided data on more than one PE threshold, then all available information was extracted (e.g. one dataset for 0.9 ng/ml and one dataset for 1.5 ng/ml). Nevertheless, no dataset was included in the same analysis more than once.
Given the known variability in the thresholds employed in order to classify patients as those with or without PE (Venetis et al., 2007) , pooling of data were performed for groups of studies/datasets based on these PE thresholds. More specifically, the following PE threshold groups were constructed: (a) 0.4-0.6 ng/ml, (b) 0.8 -1.1 ng/ml, (c) 1.2 -1.4 ng/ml, (d) 1.5 -1.75 ng/ml and (e) 1.9 -3.0 ng/ml. Nevertheless, for reasons of completeness, pooled data for the main outcome measure on every individual PE threshold reported in the literature are also reported in this meta-analysis.
These results were combined for meta-analysis using the inverse variance method (Hedges and Olkin, 1985) , when using the fixed effects model, and the DerSimonian and Laird method (DerSimonian and Laird, 1986), when using the random effects model. When the outcome of interest was of a continuous nature, the differences were pooled across the studies which provided information on this outcome, resulting in a weighted mean difference (WMD) with 95% CI. All results were combined for meta-analysis with Comprehensive Meta-Analysis (Version 2 Biostat, Englewood, NJ, USA). Forest plots were constructed with the use of Microsoft Excel 2011 for Mac (v.14.0, Microsoft Corp, USA). Metaregression analyses were performed using the 'metareg' module available for STATA (Version 12.0, College Station, TX: StataCorp LP).
Study-to-study variation was assessed by using the x 2 statistic (the hypothesis tested was that the studies are all drawn from the same population, i.e. from a population with the same effect size). In addition, the use of the I 2 index was employed in order to indicate the proportion of inconsistency between studies that could not be attributed to chance, with I 2 ≥ 50% indicating significant heterogeneity (Higgins et al., 2003) . A fixed effects model was used where no statistically significant heterogeneity was present, whereas in the presence of significant heterogeneity, as indicated either by the x 2 statistic or the I 2 index, a random effects model was applied. Statistical significance was set at P , 0.05. The presence of publication bias was assessed by constructing and visually examining funnel plots, as well as by performing Egger's test (Egger et al., 1997) . Furthermore, the trim-and-fill method was applied in order to check for funnel plot asymmetries in an objective way. Trim-and-fill is an iterative non-parametric method used to investigate the number of 'missing' studies in a meta-analysis due to funnel plot asymmetry and calculates an 'adjusted' pooled estimate with the addition of those 'missing' studies (Duval and Tweedie, 2000) .
Additional analyses

Subgroup analyses
In the fresh IVF cycles, subgroup analyses were a priori planned to be performed according to: (a) the type of population analysed [datasets performed explicitly in poor responders, datasets performed explicitly in high responders/polycystic ovary syndrome (PCOS) patients and the remaining datasets, i.e. those not performed explicitly in high responders/PCOS patients or in poor responders] and (b) the developmental stage of embryos at transfer (cleavage versus blastocyst).
Meta-regression
The potential effect of various moderators on the association of PE with the probability of pregnancy achievement, while controlling for the effect of the different PE thresholds employed in the various datasets, was explored by using meta-regression analysis. In all cases, random effects meta-regression (Thompson and Higgins, 2002) was employed with the algorithm of restricted maximum likelihood estimation (Thompson and Sharp, 1999) .
Considering that some of the eligible studies included more than one cycle per patient, which has been suggested to increase the probability of type I error (Zimmerman et al., 1993) , meta-regression analysis was performed to test the effect of this confounder on the results of the meta-analysis. A similar procedure was followed in order explore the potential effect of the type of study design (prospective versus retrospective) on the results obtained.
Meta-analysis of PE rate
In an attempt to estimate the proportion of PE in the fresh IVF cycles, a meta-analytic methodology was employed in order to pool the data on the PE rate from different studies. The use of a fixed or a random effects model was based on the assessment of statistical heterogeneity. Subgroup analyses were performed according to: (a) the type of GnRH analogue used for pituitary suppression (GnRH agonists versus GnRH antagonists); (b) the type of gonadotrophin used for ovarian stimulation (LH-containing or not); and (c) the type of population analysed (datasets performed explicitly in poor responders, datasets explicitly in high responders/PCOS patients and the remaining datasets, i.e. those not performed explicitly in high responders/PCOS patients or in poor responders).
Clinical implications of PE on the individual and the whole IVF population
The transformation of the pooled ORs (and their 95% CIs) to absolute risk reduction and subsequently to number-needed-to-harm (NNH) was considered necessary in order to provide a clinically meaningful measure of the effect of PE. This transformation was performed by using a standard methodology proposed by the Cochrane Collaboration (Schunemann et al., 2011) . This methodology assumes that the OR remains relatively constant across a range of baseline risks, drawn from the studies included in the meta-analysis (Cates, 2002; Furukawa et al., 2002) .
Moreover, the impact of PE on the population of an IVF centre was assessed by plotting the expected pregnancy rates in that population over a range of PE rates.
Results
The initial electronic search yielded 5746 studies, while hand-searching identified three more, potentially eligible, records. After the removal of duplicates, 4413 studies comprised the initial dataset. The titles of these studies were screened and 137 publications were considered relevant to the research questions posed in this systematic review and meta-analysis. Subsequently, evaluation of the abstracts led to the identification of 92 publications, potentially appropriate for inclusion. The full-text of these publications was scrutinized resulting in the exclusion of 24 studies (Supplementary data, Table SII). Eventually, 68 studies were considered eligible for inclusion (Fig. 1) .
Systematic review
Fresh IVF cycles
In total, 63 publications contained data on the association of PE on the day of hCG administration with the probability of pregnancy achievement in women undergoing fresh IVF cycles (Edelstein et al., 1990; Schoolcraft et al., 1991; Silverberg et al., 1991; Antoine et al., 1992; Check et al., 1993a Check et al., , b, 1994 Fanchin et al., 1993 Fanchin et al., , 1997a Gonen et al., 1993; Givens et al., 1994; Shechter et al., 1994; Harada et al., 1995; Levy et al., 1995; Ubaldi et al., 1995 Ubaldi et al., , 1996a Yovel et al., 1995; Abuzeid and Sasy, 1996; Hofmann et al., 1996; Huang et al., 1996; Miller et al., 1996; Shulman et al., 1996; Moffitt et al., 1997; Doldi et al., 1999; Lindheim et al., 1999; Urman et al., 1999; Shapiro et al., 2002; Valencia et al., 2002; Zimerman et al., 2002; Bosch et al., 2003 Bosch et al., , 2010 Martinez et al., 2004; Andersen et al., 2006; Berin et al., 2006; Eleno et al., 2006; Azem et al., 2008; Li et al., 2008; Papanikolaou et al., 2009 Papanikolaou et al., , 2012 Saleh et al., 2009; Segal et al., 2009; Kilicdag et al., 2010; Seow et al., 2010; Yu et al., 2010; Elgindy, 2011; Guijarro Ponce and Nunez Calonge, 2011; Yding Andersen et al., 2011; Cohen-Bacrie et al., 2012; Devroey et al., 2012; Fatemi et al., 2012; Gordon et al., 2012; Huang et al., 2012a; Keltz et al., 2012; Kyrou et al., 2012; Lahoud et al., 2012; Ochsenkuhn et al., 2012; Peng et al., 2012; Rezaee et al., 2012; Wu et al., 2012; Xu et al., 2012) . The above studies, published during 1990 -2012, included 55 199 cycles in total, with the study sample size ranging from 24 to 11 055 cycles (median study size: 242 cycles; Table I ).
Progesterone elevation and probability of pregnancy Some of these studies provided data on the association of PE with the probability of pregnancy achievement in specific subgroups of patients, which were extracted for the purposes of this meta-analysis. More specifically, data were obtained from: (a) three studies according to the type of gonadotrophin used for ovarian stimulation (hMG versus follitropin; Antoine et al., 1992; Andersen et al., 2006; Devroey et al., 2012) ; (b) three studies according to the type of ovarian response (low, intermediate and high responders; Fanchin et al., 1997b; Gordon et al., 2012; Xu et al., 2012) , and one study regarding the association of PE with pregnancy rates in women with PCOS and women without PCOS (Doldi et al., 1999) ; (c) three studies on type of GnRH analogue used for pituitary suppression (agonists versus antagonists; Bosch et al., 2010; Huang et al., 2012a; Papanikolaou et al., 2012) ; and (d) two studies which evaluated the association between PE and pregnancy achievement separately in patients in whom embryos were transferred at the cleavage stage and in patients in whom embryos were transferred at the blastocyst stage (Papanikolaou et al., 2009; Elgindy, 2011) . In the study by Gordon et al. (2012) , data regarding PE and the probability of pregnancy achievement originating from six randomized controlled trials (RCTs) performed to answer a different research question (the European Orgalutran study, the European Middle East Orgalutran study, the North American Ganirelix study, the Engage trial, the Ensure trial and the Xpect trial) were extracted . These data had not been reported in the original publication describing the results of these RCTs.
Out of the 63 publications evaluating the prognostic role of PE on the day of hCG administration for the probability of pregnancy in fresh IVF cycles, 11 described the results of prospective studies, 6 were exploratory (retrospective) analyses of data prospectively collected for other research purposes, whereas the remaining studies were either retrospective (n ¼ 42) or the study design was not reported (n ¼ 4; Table I ).
The type of population evaluated in each study varied, from explicit subgroups of patients (e.g. poor responders) to an unselected population undergoing IVF with GnRH analogues and gonadotrophins. Details regarding the type of population examined in each study are presented in Table I .
Regarding the type of GnRH analogue used for prevention of the spontaneous LH surge, 12 studies employed GnRH antagonists, in Continued 43 studies GnRH agonists were used, in five studies pituitary suppression was performed with either GnRH agonists or GnRH antagonists, while in the remaining three studies this information was not reported (Table I) . Ovarian stimulation in the population analysed was performed in 21 studies with the use of FSH or hMG or a combination of both, while in one study recombinant LH was added to recombinant FSH. The remaining studies included patients who were stimulated with gonadotrophins (either urinary or recombinant) devoid of LH activity (n ¼ 19) or with gonadotrophins with LH activity (hMG; n ¼ 17) while in five cases the type of gonadotrophin used for ovarian stimulation was not reported (Table I) . The thresholds used to classify patients into those with and those without PE varied among studies (range: 0.4-3.0 ng/ml; Table I ). Twelve studies reported data on the association of PE with the probability of pregnancy achievement for more than one PE thresholds, while in the remaining studies (n ¼ 51) relevant data using a single PE threshold were reported. The optimal threshold for classifying patients into those with and those without PE on the day of hCG was determined by a formal receiver operating characteristic (ROC) analysis in 11 studies. In 52 studies, this PE threshold was chosen based either on previous literature (arbitrarily) or on other data-driven methods (i.e. exploratory statistical testing; Table I ). The progesterone assays used in the eligible studies are presented in Supplementary data, Table SIII .
Frozen -thawed embryo transfer cycles
Nine studies were identified providing data on the association of PE on the day of hCG administration during a stimulation cycle with pregnancy rates after a subsequent frozen-thawed transfer of embryos obtained from that cycle (Check et al., 1993b; Moffitt et The eligible studies had a study size ranging from 73 to 4021 cycles (median size: 333 cycles; n ¼ 7229 cycles in total). Most of the included studies were retrospective (n ¼ 7), one study was an exploratory analysis of data collected for an RCT evaluating a different research question (Al-Azemi et al., 2012), while one study was prospective in design (Li et al., 2008;  Table II) .
The inclusion criteria utilized in the eligible studies varied (Supplementary data, Table SIV ). Gonadotrophin-releasing hormone agonists were used for pituitary suppression in the fresh IVF cycle in eight out of nine studies (Table II) . The preparation of the endometrium in the recipient was achieved as follows: (a) through either artificial hormonal preparation or a natural cycle in four studies and (b) exclusively through artificial hormone preparation (n ¼ 1), while (c) in four studies the type of endometrial preparation was not reported.
The thresholds used to classify patients in those with and those without PE also varied among studies (range: 0.9-2.5 ng/ml), with most studies providing extractable data for only a single PE threshold (n ¼ 6). The determination of the PE threshold was based on arbitrary methods in seven out of nine studies, while in the remaining two studies, a ROC analysis using the data from the fresh IVF cycle was employed for that purpose (Table II) .
Recipient cycles with donated oocytes
Eight retrospective studies had extractable data on the association of PE on the day of hCG administration in the donor cycle, with the pregnancy rates observed in the recipient (Hofmann et al., 1993; Legro et al., 1993; Check et al., 1994 Check et al., , 2010 Yovel et al., 1995; Fanchin et al., 1996; Shulman et al., 1996; Melo et al., 2006 n ¼ 1330 cycles in total; Table III ). Three studies used the egg-sharing model (Check et al., 1994; Yovel et al., 1995; Shulman et al., 1996) , while the remaining five studies included designated oocyte donors (Supplementary data, Table SV ). The PE thresholds used in these studies varied (range: 0.9 -2.47 ng/ ml) and in two studies, data on the association of PE in the donor cycle with the probability of pregnancy in the recipient cycle were extracted for more than one PE threshold (Legro et al., 1993; Check et al., 2010 ; Table III ). The PE threshold was chosen arbitrarily in most studies (n ¼ 7), whereas in one study (Check et al., 2010) , a distribution analysis was used.
Meta-analysis
Proportion of PE (PE rate) in fresh IVF cycles
The pooled rates of PE varied according to the thresholds employed (Table IV) , ranging from 46.7% when using thresholds as low as 0.4-0.6 ng/ml to 12.3% when using thresholds 1.9-3.0 ng/ml. The random effects model was used for meta-analytic pooling because of the substantial amount of heterogeneity present. A meta-regression analysis, using the logit of the PE rate of each study as the dependent variable and the threshold level used to define PE as a continuous covariate, indicated that the PE threshold employed was negatively correlated with the logit of the proportion of PE [coefficient (coeff.): 21.05, 95% CI: 21.72 to 20.38; P ¼ 0.002; Fig. 2 ].
The pooled rates of PE according to the PE threshold groups were subsequently analysed taking into account the following potential effect moderators: (a) the type of GnRH analogue, (b) the type of gonadotrophin and (c) the type of population (Table IV) . A significant amount of heterogeneity was noted between subgroups (e.g. agonists versus antagonists versus mixed) across the various PE threshold groups used, which, however, did not reveal a consistent moderating effect. Exploratory meta-regression analyses were performed in order to test for the presence of an effect of these moderators on PE rates. In all meta-regression analyses the dependent variable was the logit of the PE rate reported, while the independent variable was the aforementioned potential effect moderators. In each model, the 'PE threshold' was used as a continuous covariate in order to control for the variance explained by the PE thresholds used in the different studies, and thus, isolate the potential effect of each moderator examined.
Meta-regression regarding the type of analogue used revealed marginally significant evidence suggesting that the use of a GnRH antagonist protocol is associated with a decreased rate of PE when compared with the GnRH agonist protocols (coeff.: 20.53, 95% CI: 21.10 to +0.03; P ¼ 0.06), irrespective of the PE threshold. This finding was not materially altered even after including in the model the type of population as an additional covariate (P ¼ 0.07).
Considering the type of gonadotrophin, the meta-regression analysis did not detect a statistically significant effect on PE rates, by comparing the studies in which LH-containing gonadotrophins were used for ovarian stimulation with those in which the gonadotrophins used did not contain LH (coeff: 20.08, 95% CI: 20.73 to +0.58; P ¼ 0.82).
The type of population evaluated in each dataset (high responders/ PCOS patients, poor responders, other type of population) was also regressed on the logit of the PE rates, after controlling for the effect of the PE threshold. This analysis indicated a non-significant increase in the PE rates, when comparing studies which were performed explicitly in poor responders with those performed in the unselected population (i.e. not performed explicitly in high responders/PCOS patients or in the poor responders population; coeff: +0.84, 95% CI: 20.42 to +2.11; P ¼ 0.19) and with studies exclusively including high responders/PCOS patients (coeff: +1.30, 95% CI: 20.18 to +2.78; P ¼ 0.08): the addition of the type of GnRH analogue as a covariate in the model did not alter the aforementioned results (P ¼ 0.19 and P ¼ 0.08, respectively).
Association of PE with primary and secondary outcome measures in fresh IVF cycles Achievement of pregnancy. The association of PE with the probability of pregnancy achievement per PE threshold group is depicted in Table V . Details regarding the association of PE with the achievement of pregnancy for individual PE thresholds reported in the literature are provided in Supplementary data, Tables SVI and SVII. † 0.4 -0.6 ng/ml PE threshold group (1.27-1.91 nmol/l).
Five datasets (n ¼ 1659 patients) were available for analysis employing PE thresholds ranging from 0.4 to 0.6 ng/ml. When these data were pooled, no statistically significant difference in the probability of pregnancy achievement between women with and those without PE was detected (OR: 0.39, 95% CI: 0.14 -1.08; heterogeneity: P , 0.001, I 2 ¼ 81.2%; random effects model; Table V; Fig. 3 ). Publication bias was not detected by Egger's test (P ¼ 0.31) and similarly, no major asymmetry was apparent by the funnel plot (Supplementary data, Fig. S1 ). This was confirmed with the trim-and-fill method, which did not lead to the imputation of any 'missing' studies.
The calculation of a pooled OR for clinical pregnancy and ongoing pregnancy/live birth (Supplementary data, Fig. S2a ) did not materially change the initial findings, since a statistically significant association between PE and clinical pregnancy or ongoing pregnancy/live birth was not detected (Table V) . † 0.8 -1.1 ng/ml PE threshold group (2.54-3.50 nmol/l).
Forty datasets (n ¼ 16 304 patients) provided information for this PE threshold range. The meta-analytic pooling of these datasets indicated that PE was associated with a decreased probability of pregnancy achievement (OR: 0.79, 95% CI: 0.67 -0.95; heterogeneity: P , 0.001, I
2 ¼ 66.8%; random effects model; Table V (Table V) . † 1.2 -1.4 ng/ml PE threshold group (3.82-4.45 nmol/l).
A negative association between PE and the probability of pregnancy achievement was also detected in studies with a PE threshold ranging from 1.2 to 1.4 ng/ml (19 datasets; n ¼ 5,885 patients; OR: 0.67, 95% CI: 0.53 -0.84; heterogeneity: P ¼ 0.003, I
2 ¼ 53.4%, random effects model; Table V ; Fig. 3 ). The presence of publication bias was unlikely (Egger's test: P ¼ 0.94). The funnel plot appeared overall quite symmetric and the application of the trim-and-fill method implied that there were no 'missing' studies that should be imputed (Supplementary data, Fig. S4 ). Pooled ORs for clinical pregnancy (OR: 0.68, 95% CI: 0.49-0.94) and ongoing pregnancy/live birth (OR: 0.64, 95% CI: 0.53 -0.77; Supplementary data, Fig. S2c ) indicated a similar negative effect in women with PE when compared with women without PE (Table V) . † 1.5 -1.75 ng/ml PE threshold group (4.77-5.56 nmol/l).
Meta-analytic pooling of 26 datasets, with 21 647 patients in total, suggested that the probability of pregnancy achievement is decreased in women with PE when compared with those without PE (OR: 0.64, 95% CI: 0.54 -0.76; heterogeneity: P , 0. Progesterone elevation and probability of pregnancy effects model; Table V (Table V) . † 1.9 -3.0 ng/ml PE threshold group (6.04-9.54 nmol/l).
There were 12 datasets (n ¼ 15 091 patients), in which the PE thresholds employed were in the range of 1.9-3.0 ng/ml for this outcome. The probability of pregnancy achievement was significantly decreased in women with PE when compared with women without PE (OR: 0.68, 95% CI: 0.51 -0.91; heterogeneity: P ¼ 0.005, I
2 ¼ 59.2%, random effects model; Table V; Fig. 3 ). The application of Egger's test did not suggest the presence of publication bias (P ¼ 0.65). The funnel plot appeared mostly symmetric, and three 'missing studies'
were imputed following the application of the trim-and-fill method (OR a ¼ 0.72, 95% CI: 0.54-0.96; Supplementary data, Fig. S6 ). Pooled ORs for ongoing pregnancy/live birth also suggested a negative effect of PE (OR: 0.67, 95% CI: 0.55 -0.81; Supplementary Fig.  S2e ). The probability of clinical pregnancy appeared decreased in women with PE when compared with those without (with an effect size similar to the previous findings), yet this result was not statistically significant (OR: 0.65, 95% CI: 0.41 -1.04; Table V ).
The association of PE with pregnancy achievement in different subgroups † Type of population.
To explore the potential effect of the type of population on the association between the presence of PE and the probability of pregnancy achievement, the datasets were classified in three categories: (a) those performed explicitly in high responders/PCOS patients; (b) those performed explicitly in poor responders; and (c) the remaining datasets (i.e. those not performed explicitly in high responders/PCOS patients or in poor responders; A meta-regression analysis was performed aiming to test the potential moderating effect of the type of population on the association of PE with the probability of pregnancy achievement, while controlling for the effect of different PE thresholds used in the studies included. The overall model was not statistically significant (P ¼ 0.08). The analysis indicated a non-significant increase in the OR, when datasets referring explicitly to poor responders were compared with datasets not referring explicitly to poor responders or high responders/PCOS patients (coeff: +0.61, 95% CI: 20.15 to +1.36). On the contrary, a statistically significant increase in the OR was present when datasets referring explicitly to poor responders were compared with datasets referring explicitly to high responders/PCOS patients (coeff: +1.00, 95% CI: +0.15 to +1.85). † Developmental stage of embryo at transfer.
A meta-regression analysis did not detect a significant moderating effect of the developmental stage of embryo at transfer (cleavage versus blastocyst stage) on the association of PE with the probability of pregnancy achievement, after controlling for the effect of the PE thresholds employed in the various datasets analysed (coeff: +0.28, 95% CI: 20.17 to +0.74; overall model: P ¼ 0.15).
Effect of non-independent data and study design
Meta-regression analysis did not indicate a significant difference in the effect sizes between studies including more than one cycle per patient, when compared with those including only one cycle from each couple (coeff: 20.07, 95% CI: 20.32 to +0.17). Similarly, no moderating effect was suggested by the meta-regression analysis, when retrospective studies were compared with prospective ones (coeff: +0.03, 95% CI: 20.37 to +0.43).
Secondary outcome measures
Details regarding the pooled WMDs between women with and without PE are reported in Table VI . † Duration of ovarian stimulation.
In total, there were 25 datasets for this outcome. No statistically significant difference was observed in the number of days required for ovarian stimulation in women with PE when compared with those without PE in four out of five PE threshold subgroups examined (Table VI) . In the 0.4 -0.6 ng/ml group, based on the results of one dataset (n ¼ 133), a statistically significant increase in the total duration of stimulation in women with PE when compared with those without PE was present (WMD: +0.7 days, 95% CI: +0.02 to +1.4; Table VI). † Total dose of FSH required for ovarian stimulation.
Regarding the total dose of FSH required for ovarian stimulation, 28 datasets were analysed. The WMD was not statistically significant in two out of the five PE threshold groups (0.8 -1.1 ng/ml and 1.2 -1.4 ng/ml; Table VI ). In the remaining three PE threshold groups, pooling of data indicated that in the presence of PE, an increased number of FSH ampoules was required for ovarian stimulation (0.4-0.6 ng/ml group: WMD: +10.5 ampoules, 95% CI: +5.7 to +15.3; 1.5-1.75 ng/ml group: WMD: +0.35 ampoules, 95% CI: +0.25 to +0.44; 1.9-3.0 ng/ml group: WMD: +0.3 ampoules, 95% CI: +0.1 to +0.5; Table VI) . † E 2 levels on the day of hCG.
Thirty-two datasets were available for this outcome. E 2 levels on the day of hCG were increased in women with PE when compared with women without PE, and this difference was statistically significant in three out of four PE threshold groups (0.8 -1.1 ng/ml, 1.5 -1.75 ng/ ml and 1.9 -3.0 ng/ml; Table VI). † Number of COCs retrieved.
The mean number of COCs retrieved was significantly increased in women with PE when compared with those without PE. This finding was consistent across all PE threshold groups and was based on the analysis of 37 datasets offering relevant information. More specifically, this difference ranged from +1.9 COCs (observed in the 1.2-1.4 ng/ ml group) to +3.1 COCs (observed in the 1.5-1.75 ng/ml group; Table VI) .
Association of PE with the probability of pregnancy achievement in frozen-thawed IVF cycles Data on the association of PE observed in a fresh cycle with the probability of pregnancy after a subsequent frozen-thawed transfer of embryos obtained from that cycle were provided by sixteen datasets. Meta-analytic pooling of these datasets suggested that there was no association between PE in the fresh IVF cycle and the probability of pregnancy achievement in a subsequent frozen-thawed cycle. This finding was consistent across all PE threshold groups evaluated. More specifically, in the 0.8-1.1 ng/ml group, the pooled OR was 1.03 (95% CI: 0.79-1.34; heterogeneity: P ¼ 0.16, I
2 ¼ 44.9% fixed effects model; three datasets, n ¼ 602 patients) and in the 1.2-1.4 ng/ml group the OR was 0.83 (95% CI: 0.62-1.1; heterogeneity: P ¼ 0.85, I 2 ¼ 0%; fixed effects model; two datasets, n ¼ 740 patients; Fig. 4a ).
Similarly, no statistically significant association between the presence of PE in the fresh cycle and the probability of pregnancy achievement in the frozen-thawed cycle was observed in the two remaining PE threshold groups (1.5-1.75 ng/ml group: OR ¼ 1.13, 95% CI: 0.97-1.32; heterogeneity: P ¼ 0.50, I 2 ¼ 0%, fixed effects model; six Association of PE with the probability of pregnancy achievement in IVF cycles using donated oocytes
Eight datasets provided information for this outcome. The meta-analysis of these data suggested that there is no evidence for an association between the presence of PE in the donor stimulation cycle with the probability of pregnancy achievement in the recipient cycle (Fig. 4b) . This finding was consistent across all PE threshold groups evaluated. In the 0.8-1.1 ng/ml group, the pooled OR for pregnancy achievement in women receiving oocytes from women exhibiting PE on the day of hCG administration was 1.18 (95% CI: 0.76-1.84; heterogeneity:
fixed effects model; five datasets, n ¼ 577 patients). Similarly, no statistically significant association between the presence of PE on the day of hCG in the donor stimulation cycle and the probability of pregnancy achievement in the recipient was observed in the 1.2-1.4 ng/ml group (OR: 1.61, 95% CI: 0.64-4.05; heterogeneity: P ¼ 0.07, I 2 ¼ 70.7%, random effects model; two datasets, n ¼ 354 patients), in the 1.5-1.75 ng/ml group (OR: 0.97, 95% CI: 0.56-1.69; heterogeneity: n/a, fixed effects model; one dataset, n ¼ 205 patients) and in the 1.9-2.5 ng/ml group (OR: 0.51, 95% CI: 0.12-2.19; heterogeneity: P ¼ 0.03, I 2 ¼ 78.6%, random effects model; two datasets, n ¼ 513 patients; Fig. 4b ).
Clinical implications of PE on the individual patient and the total population of an IVF centre
Given the significant negative effect of PE on the probability of pregnancy achievement in fresh cycles, demonstrated in the present meta-analysis, the pooled ORs were translated in, the much more clinically interpretable, NNH, across a range of baseline pregnancy rates (i.e. pregnancy rates in the population that does not exhibit PE on the day of hCG administration). Considering that when all datasets were combined, the strongest effect size of PE for achievement of pregnancy was observed in the 1.5-1.75 ng/ml PE threshold group (OR: 0.64, 95% CI: 0.54 -0.76); the absolute pregnancy rate reduction (APRR) and the corresponding NNH (with their 95% CIs) are presented in Fig. 5a and b, across baseline pregnancy rates ranging from 5 to 50%. For a baseline pregnancy rate of 40%, the absolute risk reduction was calculated to be 10.1% (95% CI: 6.4-13.5) and the corresponding NNH ¼ 9.9 (95% CI: 7.4-15.7). For the individual patient, this is translated to a decrease in the expected pregnancy rate from 40% (in the absence of PE) to 29.9% (in the presence of PE).
To evaluate the impact of PE on the total population of an IVF centre, both the baseline pregnancy rate and the PE rate in that population are required. In Figure 5c , the expected pregnancy rate in the population (with a baseline pregnancy rate of 40%) is plotted according to different PE rates, ranging from 5 to 35%, using a PE threshold of 1.5 -1.75 ng/ml. Thus, assuming that the PE rate is 17.2% in this population (which in this meta-analysis has been calculated to be the pooled estimate for PE rate in the 1.5-1.75 ng/ml group; Table IV), the expected pregnancy rate in the total population of an IVF centre would be 38.3% (APRR: 1.7%, 95% CI: 1.1-2.3) 
Discussion
Main findings
This systematic review and meta-analysis shows that PE on the day of hCG administration is associated with a significantly decreased probability of pregnancy after fresh embryo transfer in women undergoing ovarian stimulation using gonadotrophins and GnRH analogues for IVF. This finding was present in all PE threshold groups evaluated, with the exception of the lowest PE threshold group (0.4 -0.6 ng/ml). On the other hand, no association between PE on the day of hCG administration in the fresh cycle and the probability of pregnancy after transfer of frozen-thawed embryos originating from that cycle was present. Similarly, women who receive oocytes from donors with PE on the day of hCG administration do not have a decreased probability of pregnancy after IVF when compared with those who receive oocytes from donors without PE.
In patients with PE it is expected that more oocytes will be retrieved. This finding was consistent in all PE threshold groups analysed. Similarly, E 2 levels on the day of hCG appear to be increased in the presence of PE, and this finding was significant in all PE threshold groups with the exception of the 1.2-1.4 ng/ml group. In addition, there was some evidence that PE is associated with an increase in the total amount of FSH used for ovarian stimulation, noted in three out of five PE threshold groups. On the other hand, this systematic review did not provide any convincing evidence that the duration of ovarian simulation is different between women with and those without PE.
Comparison with previous meta-analyses
Two previous meta-analyses evaluated the association between PE on the day of hCG administration and the probability of pregnancy in cycles in which a fresh embryo transfer was performed using the patient's oocytes (Venetis et al., 2007; Kolibianakis et al., 2012) . The first meta-analysis (five studies; n ¼ 700 patients) showed a lower, although not significantly so, pregnancy rate in the presence of PE (Venetis et al., 2007) . A subsequent meta-analysis, focusing only on GnRH antagonist co-treated cycles (five studies; n ¼ 585 patients), suggested that significantly lower pregnancy rates should be expected in the presence of PE . The current meta-analysis evaluated 63 studies (n ¼ 55 199 cycles) in fresh IVF cycles over a range of PE thresholds (0.4-3.0 ng/ml). Moreover, the prognostic role of PE on the day of hCG administration in frozen -thawed (9 studies; n ¼ 7,229 cycles) and donor/recipient cycles (8 studies; n ¼ 1330 cycles) was also appraised. The large number of eligible studies allowed for a more sophisticated exploration of the heterogeneity with the use of meta-regression analyses, which was not possible in the previous meta-analyses. Furthermore, the current meta-analysis estimated the proportion of PE in various populations by using various PE thresholds.
It should be noted that a relative consistency in the main findings of the two previously published meta-analyses and the current one is noted by examining their effect sizes. Regarding secondary outcome measures, an increased number of COCs retrieved in women with PE when compared with women without PE was also noted in the two previous meta-analyses (Venetis et al., 2007; Kolibianakis et al., 2012) . Furthermore, agreement seems to be present between the current and the previous meta-analyses regarding the E 2 levels on the day of hCG administration, which appear to be increased in patients with PE, and the duration of FSH stimulation, which does not appear to be different between patients with PE when compared with those without PE. A small increase in the total dose of FSH required for ovarian stimulation in women with PE was present in all meta-analyses, however, evidence suggesting that this might not be a chance finding was provided only in the current one.
Limitations of the current meta-analysis
The studies analysed in the present meta-analysis are observational and thus, in most cases, the presence of bias cannot be excluded. Imbalances in the characteristics of the two groups compared in each study (patients with or without PE) might confound the association of PE with the probability of pregnancy. In an attempt to minimize the potential effect of bias in the results of this meta-analysis, studies reporting significantly different number of embryos transferred between women with and without PE were excluded. Similarly, studies in which it was reported that the values of progesterone on the day of hCG affected the way patients were managed were also not considered eligible.
In terms of design, both retrospective and prospective studies were included. Retrospective studies are considered methodologically inferior and are prone to bias. However, a meta-regression analysis did not reveal any difference between the effect sizes of prospective and retrospective studies. A sensitivity analysis performed by pooling (a) only prospectively collected data or (b) data originating from randomized trials (designed to evaluate a different research question) did not show the presence of significant systematic error in retrospective studies (Supplementary Table SVIII ). This indicates that the inclusion of Figure 4 Pooled OR for achievement of pregnancy in women: (a) Forest plots of odds ratios (OR) for achievement of pregnancy in women undergoing frozen-thawed embryo transfer after a fresh cycle with or without progesterone elevation (PE) (per PE threshold group) and (b) Forest plots of odds ratios (OR) for achievement of pregnancy in women undergoing embryo transfer with donated oocytes from women who did or did not experience progesterone elevation (PE) (per PE threshold group).
Progesterone elevation and probability of pregnancy retrospective studies in the current meta-analysis is not likely to have biased the results. In addition, the inclusion of studies in which some couples contributed more than one cycle is a source of concern, since it has been shown to be associated with inflated P-values (Zimmerman et al., 1993) . Nevertheless, a meta-regression analysis failed to detect a significant difference in the effect sizes between studies reporting independent and those reporting non-independent data.
The included studies exhibit marked clinical heterogeneity in the way ovarian stimulation was performed, the methods used to measure progesterone and the type of population analysed. For these reasons, a random effects model was used, when any indication of heterogeneity was present. In addition, an attempt was made to explore heterogeneity by means of meta-regression analyses. However, although heterogeneity is expected to cause statistical noise and hamper the detection of an effect, the presence of a lower pregnancy rate in women with PE across all PE threshold groups evaluated strengthens the validity of the conclusions drawn.
Interpretation of the findings
PE is not an infrequent phenomenon. Not unexpectedly, as the PE threshold increases, the proportion of patients with PE decreases. Moreover, a meta-regression analysis provided indications (P ¼ 0.06) that the use of GnRH antagonists might be associated with decreased PE rates when compared with the use of GnRH agonists. This finding might be explained by the fact that more oocytes are retrieved in GnRH agonist when compared with GnRH antagonist cycles (Kolibianakis et al., 2006) .
The detrimental effect of PE on the probability of pregnancy achievement in women undergoing fresh IVF cycles seems to be present, already from progesterone concentrations in the range of 0.8-1.1 ng/ml (OR: 0.79) and appears to be increased when progesterone concentration reaches 1.2 ng/ml or more (Fig. 6) . Interestingly, this effect appears relatively stable after 1.2 ng/ml (Fig. 6) , perhaps indicating the maximal effect of PE on the probability of pregnancy Figure 5 Graphical representation of the transformation of the OR:0.64 (95% CI: 0.54-0.76) to (a) Absolute pregnancy rate reduction with 95% CIs (dotted lines) and (b) NNH with 95% CIs (dotted lines), according to a range of baseline pregnancy risks. Based on these calculations, graph (c) depicts the expected pregnancy rate with 95% CIs (dotted lines) in a population with 40% baseline pregnancy rate (i.e. pregnancy rate in the non-PE patients) according to a range of PE rates in that population. achievement in the general IVF population undergoing a fresh embryo transfer. Moreover, this finding is in agreement with previous evidence suggesting the presence of a nonlinear effect of PE on the probability of pregnancy (Bosch et al., 2010) .
The detrimental effect of PE on pregnancy rates is hypothesized to be exerted through its action on the endometrium (Hofmann et al., 1993; Fanchin et al., 1996; Chetkowski et al., 1997; Melo et al., 2006) . The current meta-analysis provides indirect evidence in support of this hypothesis, considering that pregnancy rates are not compromised when embryos obtained from cycles with PE are transferred to endometria not exposed to PE (i.e. in frozen-thawed or in donor/recipient cycles). Direct evidence for an effect of PE on the endometrium has been provided by endometrial gene expression analysis (Labarta et al., 2011; Li et al., 2011; Van Vaerenbergh et al., 2011) .
It has been suggested that ovarian response might be a moderating factor on the association of PE with the probability of pregnancy (Fanchin et al., 1997b; Xu et al., 2012) , although others have challenged this idea (Bosch et al., 2010) . Based on the results of the current meta-analysis, a detrimental effect of PE is present already from 0.8 to 1.1 ng/ml (Table V) in the general IVF population and in the poor responders. In the high responders, however, it appears that such an effect of PE on the probability of pregnancy achievement is exhibited only when the level of serum progesterone on the day of hCG reaches 1.9-3.0 ng/ml (Fig. 6) . This indicates that an increased oocyte yield might compensate for the detrimental effect of PE on the endometrium.
It has been suggested that a lower pregnancy rate in the presence of PE is observed when embryos are transferred at the cleavage stage, while such an effect is not observed when embryos are transferred at the blastocyst stage (Papanikolaou et al., 2009) . A meta-regression analysis failed to detect a potential moderating effect of the developmental stage of embryos at transfer on the association of PE with pregnancy. The number of studies providing data, however, is still small and for this reason the probability of a type II error should also be considered.
Implications for clinical practice
It is clear that in patients undergoing a fresh embryo transfer, PE on the day of hCG administration is associated with a decreased probability of pregnancy. In the example illustrated in this analysis, assuming an OR for pregnancy of 0.64 (PE threshold group: 1.5-1.75 ng/ml) and a baseline pregnancy rate of 40%, the expected APRR would be 10%. For the individual patient, this effect is clinically important. The corresponding NNH is 10, which means that for every 10 patients with PE, three instead of four pregnancies should be expected.
On the other hand, this effect of PE on the overall pregnancy rate of an IVF population is expected to be variable, since the proportion of patients with PE may fluctuate. In the example provided in this meta-analysis, using a PE rate of 17.2%, the APRR in the population is 1.7%. This means that if progesterone on the day of hCG is assessed in 1000 patients, it will be elevated in 172 cases. If an intervention (able to counteract the effect of PE) is performed in these 172 Figure 6 Pooled OR for achievement of pregnancy in women with or without PE according to type of study analysed (dotted lines represented 95% CIs, POR, poor ovarian response; PCOS, polycystic ovary syndrome).
Progesterone elevation and probability of pregnancy patients, then (based on the NNH 10) 17 pregnancies will be rescued. Whether this expected benefit justifies the implementation of a specific policy in the 1000 patients remains a debatable issue, especially in the absence of hard evidence showing an effective way of managing patients with PE.
Implications for future research
Considering the clinical implications of PE for women undergoing ovarian stimulation for IVF, it is clear that further research in this field is warranted. Ideally, an individual patient data meta-analysis of sufficient size would allow for the identification of parameters (patient characteristics, type of ovarian response, quantity and quality of available embryos etc.) that might moderate the detrimental effect of PE on the probability of pregnancy for the individual patient. Furthermore, such an analysis might allow for calculation of the independent effect of PE on the probability of pregnancy achievement. In this way, the construction of a multivariate, nonlinear, predictive model that will provide a reliable assessment of the prognosis for each patient might be feasible. Although the development and validation of such a model is not an easy task, it might be the most appropriate tool for the physician counselling each subfertile couple regarding the optimal treatment.
Several approaches have been proposed in order to prevent PE (Al-Azemi et al., 2012; Kyrou et al., 2012) . Most importantly though, there is an urgent need for providing solid evidence regarding the most effective way of managing women with PE on the day of hCG administration. Freezing embryos and transferring them in a subsequent frozen-thawed cycle (the 'freeze-all' strategy) has been proposed as a way to bypass impaired endometrial receptivity (Aflatoonian et al., 2010; Shapiro et al., 2011) , and it is also considered to be the most frequently used method for managing PE (Shapiro et al., 2010) . Surprisingly, no RCT to date has evaluated the effectiveness of this intervention in women who exhibit PE on the day of hCG administration. Until such data are available, the inference that the 'freeze-all' strategy is a better option than a fresh transfer in women with PE is made on the basis of indirect or low-quality evidence.
Conclusions
Based on the analysis of more than 60 000 cycles, it can be supported that PE on the day of hCG administration is associated with a decreased probability of pregnancy achievement in fresh IVF cycles in women undergoing ovarian stimulation using GnRH analogues and gonadotrophins. On the other hand, a negative association between PE on the day of hCG administration in the fresh cycle and the probability of pregnancy after transfer of frozen-thawed embryos originating from that cycle does not seem to be present. Similarly, women who receive oocytes from donors with PE on the day of hCG administration do not appear to have a decreased probability of pregnancy after IVF when compared with those who receive oocytes from donors without PE.
